Notably, the clearance of B2M in the serum of AD mice effectively improved the pathological characteristics of AD (Zhao et al. 2023), which suggested targeting B2M might as a novel and viable therapeutic strategy for future clinical treatment of AD. This evidence concerns the gene B2M and Alzheimer disease.